Table 2.
Summary of results of simulations indicating probabilities for arriving at platform conclusions (effectiveness or futility) in each domain with varying sample sizes and effect sizes. The probabilities for arriving at platform conclusions can be conceptualised as similar to the power of the study
Antiviral domain | Anticoagulation domain | Antibody domain | ||||
---|---|---|---|---|---|---|
Treatment arms | 2 | 3 | 2 | |||
Estimated sample size | 2000 | 3200 | 1600 | |||
Odds ratio (effect) | Effective | Futile | Effective | Futile | Effective | Futile |
1.10 (harmful) | 0.01 | 0.89 | 0.00 | 0.80 | 0.01 | 0.83 |
1.00 (null) | 0.03 | 0.67 | 0.03 | 0.53 | 0.03 | 0.58 |
0.80 (weak) | 0.37 | 0.10 | 0.50 | 0.07 | 0.30 | 0.10 |
0.67 (moderate) | 0.84 | 0.01 | 0.93 | 0.01 | 0.75 | 0.01 |
0.50 (strong) | 1.00 | 0.00 | 1.00 | 0.00 | 0.99 | 0.00 |